Sign In
Buy JNJ
$239.08
+7.79 (+3.37%)
At Close: Jun 23, 2026
How To Build A $1,000,000 Dividend Portfolio That Could Yield 11%+ In 15 Years
11:00am, Tuesday, 24'th Jun 2025
The Dividend Income Accelerator Portfolio balances income, growth, and capital appreciation, now enhanced by the global diversification from Allianz and LVMH. We focus on financially healthy companies
Best Dividend Kings: June 2025
08:49am, Tuesday, 24'th Jun 2025
Dividend Kings have underperformed the S&P 500 year-to-date, but 26 are outperforming SPY in 2025, with 32 posting positive returns. Dividend growth remains healthy, with four recent increases and a c
5 Dividend Stocks Poised to Profit From the AI Efficiency Boom
08:00am, Tuesday, 24'th Jun 2025
When companies deploy artificial intelligence (AI) to streamline operations, the results can be staggering. Microsoft (MSFT 1.88%) is using AI-powered code-completion tools to help developers write co
2 Dividend Aristocrats Bargains To Buy And 'Never Let Go'
08:00am, Tuesday, 24'th Jun 2025
Buying Dividend Aristocrats at bargain prices can be a winning investment strategy. I highlight two such names that are undervalued compared to historical norms while paying strong and well-covered di
J&J Adds More Than $15B in Six Months: How to Play JNJ Stock?
10:25am, Monday, 23'rd Jun 2025
JNJ stock added $15B in market value in six months as new drug launches offset MedTech and Stelara headwinds.
J&J's Drugs Get CHMP Recommendations for Blood Cancer Indications
10:15am, Monday, 23'rd Jun 2025
JNJ wins CHMP backing for Darzalex and Imbruvica in new blood cancer uses, paving the way for first-in-class approvals.
Trump’s Fellow College Alumni is Quite The List
10:00am, Monday, 23'rd Jun 2025
The 45th and 47th President of the United States, Donald Trump, is famously known for attending the University of Pennsylvania. Having started his college career at Fordham University, the president l
The ITC compared all published Phase 3 data of these treatments, leveraging longitudinal results, and findings reinforce the importance of consistent, sustained disease control in managing a chronic a
If I Could Only Buy 2 Dividend Stocks: June's Top Picks For Global Diversification
02:00pm, Friday, 20'th Jun 2025
I added Allianz and LVMH to The Dividend Income Accelerator Portfolio for their blend of dividend yield, growth, and financial strength. Both companies offer strong dividend growth potential—Allianz
Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know
10:01am, Thursday, 19'th Jun 2025
Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Johnson & Johnson Hit With $8M Verdict in Massachusetts Mesothelioma Talc Lawsuit
06:43pm, Wednesday, 18'th Jun 2025
BOSTON--(BUSINESS WIRE)--A Suffolk County jury has awarded $8 million in favor of Janice Paluzzi, a Massachusetts woman who developed mesothelioma after decades of using Johnson & Johnson's (NYSE:JNJ)
Smart Moves With $5,000: Dividend Stocks to Own Amid Market Chaos
11:56am, Wednesday, 18'th Jun 2025
Allocating 10% to 20% to dividend stocks balances growth-heavy portfolios, leveraging compounding returns to navigate geopolitical and monetary challenges.
2 Dividend Stocks to Buy and Never Sell
05:02am, Wednesday, 18'th Jun 2025
There are excellent reasons to invest in dividend stocks, including the fact that they typically outperform their non-dividend-paying peers in delivering strong market returns over long periods.
Johnson & Johnson CEO: “We're in the Golden Era of Medical Innovation”
03:38pm, Tuesday, 17'th Jun 2025
Johnson & Johnson Chairman and CEO Joaquin Duato believes that we are now in a “golden era” of innovation, particularly in the United States. Venture capital plays a vital early-stage role, but bi
I'm Buying Dividend Aristocrats At Bargain Basement Prices
08:00am, Tuesday, 17'th Jun 2025
Now is an opportune time to focus on income stocks like that offer value and stability amid market volatility. I focus on 2 Dividend Aristocrats that are attractively valued while supporting well-cove
